We updated the design of this site on September 25th. Learn more.

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00210743

First Posted: September 21, 2005

Last Update Posted: May 23, 2011

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Collaborator:

Ortho Biotech Products, L.P.

Information provided by:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Purpose

The purpose of this study is to evaluate the hemoglobin response rate in subjects with anemia, associated with chronic kidney failure, after receiving epoetin alfa (PROCRITÂ®) every 2 weeks

Condition	Intervention	Phase
Anemia Kidney Diseases	Drug: epoetin alfa	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	An Open-Label, Clinical Evaluation of the Initiation of Every 2 Week Epoetin Alfa (PROCRIT)in the Treatment of Subjects With the Anemia of Chronic Kidney Disease (CKD)

Resource links provided by NLM:

MedlinePlus related topics: Anemia Kidney Diseases

Drug Information available for: Epoetin Alfa

U.S. FDA Resources

Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Primary Outcome Measures:

The primary endpoint is the number of subjects who achieve a hemoglobin response after receiving PROCRIT every 2 weeks. Hemoglobin response is defined as achieving a target hemoglobin range of 11-12 g/dL for at least 2 consecutive weeks by Week 28.

Secondary Outcome Measures:

The secondary endpoints include: the time to a hemoglobin response, the number of subjects achieving a 1 g/dL rise in hemoglobin, change in quality of life measurements, and the total study drug dose up to the time of response.


Enrollment:	67
Study Start Date:	May 2004
Study Completion Date:	October 2005

Detailed Description:

This is a prospective study in non-dialysis subjects with anemia associated with chronic kidney disease. Subjects will be enrolled from multiple centers in the United States. The primary objective of the study is to evaluate hemoglobin response rate. The secondary objectives include evaluating the time to when hemoglobin responds, indicated by the results of the hemoglobin blood levels, the change in hemoglobin over time, the transfusion requirements and change in quality of life measurements. These measurements asks for the subjects views about how one feels, activity and energy level, etc. The subjects are administered study drug every 2 weeks through Study Week 27 unless dosing is held or the subject withdraws from the study. Each injection of study drug should not exceed 1 ml in volume.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects with chronic kidney disease and a glomerular filtration rate within 10-60 ml/min/1.73m2 with no expected need for dialysis during the study
subjects with a hemoglobin less than 11 g/dL
subjects who have not received erythropoietic agents within 6 weeks before study entry
female subjects, with a reproductive potential, must have a negative urine pregnancy test within 7 days of the first dose of study drug.

Exclusion Criteria:

Subjects with poorly controlled high blood pressure (hypertension) - systolic > 150 mm Hg or diastolic > 100 mm Hg
known hypersensitivity to human albumin and/or mammalian cell-derived products
subjects receiving dialysis
subjects with a ferritin level < 50 ng/mL, Transferrin Saturation < 20%
subjects receiving chemotherapy for cancer within 1 month prior to study start or expected during study participation
Pregnancy or lactation.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00210743

Sponsors and Collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Ortho Biotech Products, L.P.

Investigators


Study Director:	Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

More Information

Additional Information:

An Open-Label, Clinical Evaluation of the Initiation of Every 2 Week PROCRIT (epoetin alfa) in the Treatment of Subjects with the Anemia of Chronic Kidney Disease This link exits the ClinicalTrials.gov site

This link exits the ClinicalTrials.gov site

Publications:

Benz R, Schmidt R, Kelly K, Wolfson M. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2007 Mar;2(2):215-21. Epub 2007 Jan 10.


ClinicalTrials.gov Identifier:	NCT00210743 History of Changes
Other Study ID Numbers:	CR004600
First Submitted:	September 13, 2005
First Posted:	September 21, 2005
Last Update Posted:	May 23, 2011
Last Verified:	April 2010

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:


Anemia chronic kidney disease erythropoetin, Epoetin alfa erythropoetin recombinant pre-dialysis

Additional relevant MeSH terms:


Anemia Kidney Diseases Renal Insufficiency, Chronic Hematologic Diseases	Urologic Diseases Renal Insufficiency Epoetin Alfa Hematinics

To Top